Developments GT submits IND for GTB-5550 TriKE in solid tumors GT Biopharma (NASDAQ: GTBP) has announced that it submitted an investigational new drug (IND) application to the FDA in December 2025 for GTB-5550 TriKE, a B7-H3-targeted natural killer (NK) cell engager for the... January 15, 2026